These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 20170986

  • 1. Assessing the chemical diversity of an hsp90 database.
    Audisio D, Messaoudi S, Ijjaali I, Dubus E, Petitet F, Peyrat JF, Brion JD, Alami M.
    Eur J Med Chem; 2010 May; 45(5):2000-9. PubMed ID: 20170986
    [Abstract] [Full Text] [Related]

  • 2. Principal component analysis on molecular descriptors as an alternative point of view in the search of new Hsp90 inhibitors.
    Lauria A, Ippolito M, Almerico AM.
    Comput Biol Chem; 2009 Oct; 33(5):386-90. PubMed ID: 19660987
    [Abstract] [Full Text] [Related]

  • 3. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A, Shi M, Golas J, Vogan E, Jacob J, Johnson M, Lee F, Nilakantan R, Petersen R, Svenson K, Chopra R, Tam MS, Wen Y, Ellingboe J, Arndt K, Boschelli F.
    J Med Chem; 2008 Feb 14; 51(3):373-5. PubMed ID: 18197612
    [Abstract] [Full Text] [Related]

  • 4. Purine-scaffold Hsp90 inhibitors.
    Chiosis G, Tao H.
    IDrugs; 2006 Nov 14; 9(11):778-82. PubMed ID: 17096299
    [Abstract] [Full Text] [Related]

  • 5. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, Sensintaffar JL, Kamal A, Lough RE, Brekken J, Lundgren K, Grecko R, Timony GA, Ran Y, Mansfield R, Fritz LC, Ulm E, Burrows FJ, Boehm MF.
    J Med Chem; 2007 Jun 14; 50(12):2767-78. PubMed ID: 17488003
    [Abstract] [Full Text] [Related]

  • 6. Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors.
    Sanam R, Tajne S, Gundla R, Vadivelan S, Machiraju PK, Dayam R, Narasu L, Jagarlapudi S, Neamati N.
    J Mol Graph Model; 2010 Feb 26; 28(6):472-7. PubMed ID: 20005756
    [Abstract] [Full Text] [Related]

  • 7. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.
    He H, Zatorska D, Kim J, Aguirre J, Llauger L, She Y, Wu N, Immormino RM, Gewirth DT, Chiosis G.
    J Med Chem; 2006 Jan 12; 49(1):381-90. PubMed ID: 16392823
    [Abstract] [Full Text] [Related]

  • 8. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.
    Wright L, Barril X, Dymock B, Sheridan L, Surgenor A, Beswick M, Drysdale M, Collier A, Massey A, Davies N, Fink A, Fromont C, Aherne W, Boxall K, Sharp S, Workman P, Hubbard RE.
    Chem Biol; 2004 Jun 12; 11(6):775-85. PubMed ID: 15217611
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
    Llauger L, He H, Kim J, Aguirre J, Rosen N, Peters U, Davies P, Chiosis G.
    J Med Chem; 2005 Apr 21; 48(8):2892-905. PubMed ID: 15828828
    [Abstract] [Full Text] [Related]

  • 10. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.
    Park H, Kim YJ, Hahn JS.
    Bioorg Med Chem Lett; 2007 Nov 15; 17(22):6345-9. PubMed ID: 17869098
    [Abstract] [Full Text] [Related]

  • 11. Orally active purine-based inhibitors of the heat shock protein 90.
    Biamonte MA, Shi J, Hong K, Hurst DC, Zhang L, Fan J, Busch DJ, Karjian PL, Maldonado AA, Sensintaffar JL, Yang YC, Kamal A, Lough RE, Lundgren K, Burrows FJ, Timony GA, Boehm MF, Kasibhatla SR.
    J Med Chem; 2006 Jan 26; 49(2):817-28. PubMed ID: 16420067
    [Abstract] [Full Text] [Related]

  • 12. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P.
    Cancer Chemother Pharmacol; 2003 Jul 26; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [Abstract] [Full Text] [Related]

  • 13. 3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone.
    Brough PA, Barril X, Beswick M, Dymock BW, Drysdale MJ, Wright L, Grant K, Massey A, Surgenor A, Workman P.
    Bioorg Med Chem Lett; 2005 Dec 01; 15(23):5197-201. PubMed ID: 16213716
    [Abstract] [Full Text] [Related]

  • 14. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J, Normant E, Porter JR, Ali JA, Dembski MS, Gao Y, Georges AT, Grenier L, Pak RH, Patterson J, Sydor JR, Tibbitts TT, Tong JK, Adams J, Palombella VJ.
    J Med Chem; 2006 Jul 27; 49(15):4606-15. PubMed ID: 16854066
    [Abstract] [Full Text] [Related]

  • 15. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
    Murray CW, Carr MG, Callaghan O, Chessari G, Congreve M, Cowan S, Coyle JE, Downham R, Figueroa E, Frederickson M, Graham B, McMenamin R, O'Brien MA, Patel S, Phillips TR, Williams G, Woodhead AJ, Woolford AJ.
    J Med Chem; 2010 Aug 26; 53(16):5942-55. PubMed ID: 20718493
    [Abstract] [Full Text] [Related]

  • 16. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
    Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, Cheung KM, Collins I, Davies NG, Drysdale MJ, Dymock B, Eccles SA, Finch H, Fink A, Hayes A, Howes R, Hubbard RE, James K, Jordan AM, Lockie A, Martins V, Massey A, Matthews TP, McDonald E, Northfield CJ, Pearl LH, Prodromou C, Ray S, Raynaud FI, Roughley SD, Sharp SY, Surgenor A, Walmsley DL, Webb P, Wood M, Workman P, Wright L.
    J Med Chem; 2008 Jan 24; 51(2):196-218. PubMed ID: 18020435
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A, Razifar P, Ide S, Rugaard Jensen M, Josephsson R, Blomqvist C, Langström B, Bergström M.
    Nucl Med Biol; 2009 Apr 24; 36(3):335-42. PubMed ID: 19324279
    [Abstract] [Full Text] [Related]

  • 18. Inside the Hsp90 inhibitors binding mode through induced fit docking.
    Lauria A, Ippolito M, Almerico AM.
    J Mol Graph Model; 2009 Feb 24; 27(6):712-22. PubMed ID: 19084447
    [Abstract] [Full Text] [Related]

  • 19. Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin.
    Knox AJ, Price T, Pawlak M, Golfis G, Flood CT, Fayne D, Williams DC, Meegan MJ, Lloyd DG.
    J Med Chem; 2009 Apr 23; 52(8):2177-80. PubMed ID: 19331414
    [Abstract] [Full Text] [Related]

  • 20. Hsp90 inhibitors and drugs from fragment and virtual screening.
    Roughley S, Wright L, Brough P, Massey A, Hubbard RE.
    Top Curr Chem; 2012 Apr 23; 317():61-82. PubMed ID: 21647838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.